ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The CRISPR/Cas9-mediated reduction in BCR-ABL oncoprotein (p210) expression in Boff-p210 cells resulted in the loss of tumorigenicity in a CML xenograft animal model.